Provided by Tiger Trade Technology Pte. Ltd.

Allarity Therapeutics Inc

1.16
+0.04504.05%
Post-market: 1.170.0150+1.30%19:18 EDT
Volume:55.51K
Turnover:63.80K
Market Cap:18.27M
PE:-1.46
High:1.20
Open:1.13
Low:1.11
Close:1.11
52wk High:1.84
52wk Low:0.7687
Shares:15.82M
Float Shares:15.79M
Volume Ratio:0.44
T/O Rate:0.35%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7895
EPS(LYR):-0.7811
ROE:-157.09%
ROA:-25.31%
PB:5.17
PE(LYR):-1.48

Loading ...

Allarity Therapeutics sets CEO consulting pay at SEK 6 million plus USD 163,043 for 2026 under amended services agreement

Reuters
·
Jun 03

Allarity Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 16

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

THOMSON REUTERS
·
May 16

Allarity Therapeutics Q1 FY26 net loss narrows to $2.75 million

Reuters
·
May 16

Allarity Therapeutics director Jesper Hoeiland files initial beneficial ownership statement

Reuters
·
May 12

Allarity Therapeutics CEO speaks at Precision Medicine Forum Europe 2026

Reuters
·
May 08

Allarity Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
May 07

Allarity says Phase 3 stenoparib manufacturing campaign stays on track for Q3 2026 completion

Reuters
·
May 05

Allarity receives notice of allowance from USPTO

TIPRANKS
·
Apr 27

Allarity Therapeutics Inc - Patent Expected to Be Formally Granted Within Three Months, Subject to Standard Administrative Procedures

THOMSON REUTERS
·
Apr 27

Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office

GlobeNewswire
·
Apr 27

Allarity says stenoparib DRP scores link to longer survival in ovarian cancer trial

Reuters
·
Apr 21

Allarity Therapeutics announces annual shareholder meeting

Reuters
·
Apr 11

BRIEF-Allarity Therapeutics Reports Full Year 2025 Financial Results And Corporate Progress

Reuters
·
Mar 31

Allarity FY25 net loss narrows to $11 million; revenue rises to $0.3 million

Reuters
·
Mar 31

Allarity Therapeutics Inc expected to post a loss of 22 cents a share - Earnings Preview

Reuters
·
Mar 27